VTE Prophylaxis — Drug-Class Hub
VTE prevention after urologic surgery depends on the operation, surgical approach, extent of lymphadenectomy, individual thrombosis risk and bleeding risk. Extended prophylaxis is well established after high-risk abdominopelvic cancer surgery, particularly radical cystectomy.[1][2][12]
This is the drug-class hub for agent selection, dosing and safety. Procedure-specific decisions, assessment of bleeding risk, antiplatelet management and interruption of chronic anticoagulation belong in Antithrombotic therapy. Treatment doses for an established DVT or PE are different from the prophylactic doses below.
VTE Risk in Urologic Surgery
Risk differs sharply by operation. Radical cystectomy has the highest symptomatic VTE rate among urologic operations, and most events occur after the patient goes home.
| Procedure | Reported symptomatic VTE | Note |
|---|---|---|
| Radical cystectomy (open or robotic) | 2.6–11.6% across series; 3.16% in the 2011–2020 NSQIP cohort | Highest-risk urologic operation.[21][20] |
| Open radical prostatectomy | 0.8–15.7% | Wide range by series; comparable to cystectomy at the upper end.[21] |
| Robotic radical prostatectomy | 0.2–0.9% | Low baseline risk.[21] |
| Open partial or radical nephrectomy | 1.0–4.4% | [21] |
| Robotic partial or radical nephrectomy | 0.7–3.9% | [21] |
After radical cystectomy, 55–58% of VTE events were diagnosed after discharge: mean postoperative day 15.2 for all VTE diagnoses in a 1,307-patient NSQIP cohort, and median postoperative day 20 (range 2–91) for postdischarge VTE cases in a 2,316-patient single-center open-cystectomy series.[19][22][18] That timing is the rationale for extended prophylaxis.
In the NSQIP analysis of 207,861 urologic cancer operations, the strongest independent predictors of VTE were cystectomy (OR 2.96), blood transfusion (OR 2.29), age 80 or older (OR 1.98), BMI 40 or more (OR 1.82), heart failure (OR 1.75), steroid use (OR 1.55), thrombocytosis (OR 1.43) and leukocytosis (OR 1.41).[20]
Who Benefits, When to Start and How Long
| Source / setting | Practical implication |
|---|---|
| ESAIC urology 2024 | Recommend pharmacologic prophylaxis for open radical cystectomy and open radical prostatectomy with extended lymphadenectomy (Grade 1A or 1B by risk stratum); suggest mechanical prophylaxis as an adjunct (Grade 2C). Most other urologic procedures require procedure and patient risk assessment. For ambulatory day surgery, recommend against both pharmacologic and mechanical prophylaxis (Grade 1B each).[12] |
| Timing in that urology guideline | Start on postoperative day 1, with hemostasis and neuraxial requirements considered; continue for 2–4 weeks when pharmacologic prophylaxis is indicated. This differs from some drug labels and cancer guidelines that start before surgery.[12] |
| AUA/ASCO/SUO 2024 muscle-invasive bladder cancer | Statement 16: give perioperative pharmacologic prophylaxis to patients undergoing radical cystectomy , combined with mechanical prophylaxis. The discussion supports considering a first dose just before induction if bleeding risk allows, and notes that up to four weeks of postoperative coverage may be beneficial; optimal timing and duration are not defined.[29] |
| ITAC 2022 cancer guidance | Four weeks of LMWH after major abdominal or pelvic cancer surgery in patients without high bleeding risk.[1] |
| ASCO 2023 update | Extended LMWH remains an option for high-risk cancer surgery; apixaban or rivaroxaban may be offered after initial LMWH/UFH, with a weak recommendation because postoperative trial evidence is limited.[2] |
| TURP and radical prostatectomy | ASH 2019 conditionally suggests against pharmacologic prophylaxis for TURP and for average patients undergoing robotic radical prostatectomy with no or limited lymphadenectomy (very-low-certainty evidence). For TURP, ASH notes that prior VTE, thrombophilia or malignancy may favor prophylaxis. ESAIC 2024 recommends pharmacologic prophylaxis for open radical prostatectomy with extended lymphadenectomy (Grade 1A or 1B by risk stratum).[3][12] |
A discharge prescription should name the total intended course and stop date, including inpatient doses, rather than automatically adding another 28 days at discharge.[1][12]
Extended-Prophylaxis Evidence
- A 2021 meta-analysis of abdominopelvic cancer surgery (68 studies, 1.63 million patients) found a 30-day VTE rate of 1.7%. Extended LMWH was associated with less clinical VTE (1.0% versus 2.1%; RR 0.48, 95% CI 0.31–0.74) without a significant increase in clinically relevant bleeding (4.0% versus 4.9%).[23]
- An earlier meta-analysis of seven randomized and prospective studies (4,807 patients) reported less VTE overall (2.6% versus 5.6%; RR 0.44) and less proximal DVT (1.4% versus 2.8%). Symptomatic PE, major bleeding and mortality did not differ significantly, and the benefit was not significant when only the randomized trials were pooled.[24]
- ACCP 2012 recommends four weeks of postoperative LMWH over limited-duration prophylaxis for high-risk patients having abdominal or pelvic cancer surgery (Grade 1B).[25]
- Procedure-level data are thin. A review of major urologic cancer operations found extended prophylaxis of net benefit after open prostatectomy and open or robotic cystectomy; the balance is closer for minimally invasive prostatectomy and nephrectomy, and no procedure-specific trial shows benefit for those.[21]
Caprini: Useful Risk Assessment, Not a Universal Treatment Cutoff
Pannucci's 2017 meta-analysis included 13 studies; 11 studies with 14,776 patients contributed VTE data. Chemoprophylaxis was associated with significant VTE reduction at Caprini scores 7–8 (OR 0.60, 95% CI 0.37–0.97) and above 8 (OR 0.41, 0.26–0.65). Most participants also received mechanical prophylaxis.[4]
ACCP 2012 ties the choice of prophylaxis to baseline risk. Scores are usually mapped as 0 (very low), 1–2 (low), 3–4 (moderate) and 5 or more (high).[25] Across specialties, a Caprini score of 5 or more is associated with a significant rise in VTE, and thresholds of 7 to 11 with a steep rise.[26]
| Baseline VTE risk (ACCP 2012) | Approach |
|---|---|
| Very low (<0.5%) | Early ambulation only |
| Low (~1.5%) | Mechanical prophylaxis, preferably IPC (Grade 2C) |
| Moderate (~3%), not at high bleeding risk | LMWH or low-dose UFH (2B) or IPC (2C) |
| High (~6%), not at high bleeding risk | LMWH or low-dose UFH (1B); suggest adding stockings or IPC (2C); four weeks of LMWH after abdominal or pelvic cancer surgery (1B) |
| Moderate to high VTE risk with high bleeding risk | IPC until bleeding risk falls, then add pharmacologic prophylaxis (2C) |
Pelvic Reconstructive and Urogynecologic Surgery
VTE risk after prolapse and incontinence surgery varies by procedure and patient factors (age, obesity, prior VTE, malignancy, prolonged operation or immobility). A 2024 systematic review modeled four-week symptomatic VTE risk without mechanical or pharmacologic prophylaxis at 1.5% after minimally invasive sacrocolpopexy with hysterectomy (3 studies, n = 1,234; 1.2–4.6% across patient-risk strata), 0.2% after vaginal prolapse repair without mesh (13 studies, n = 73,626), and <0.1% after vaginal sling surgery (7 studies, n = 55,472).[30] For vaginal prolapse repair without mesh, with or without hysterectomy, the review modeled four-week bleeding requiring reintervention at 0.9% (4 studies; n = 1,050) without mechanical or pharmacologic prophylaxis.[30] ACOG Practice Bulletin 232 (2021) is the current gynecologic-surgery guidance and replaces Practice Bulletin 84; it uses a risk-based approach that pairs mechanical prophylaxis with pharmacologic prophylaxis as risk rises. ASH 2019 suggests pharmacologic prophylaxis over none for major gynecologic surgery.[16][3] In a retrospective Premier database cohort of 214,427 prolapse operations, a single perioperative pharmacologic dose (13.7% of patients) was associated with more composite bleeding complications within 3 months (1.1% versus 0.7%) and slightly more VTE (0.23% versus 0.16%).[17]
Enoxaparin — Low-Molecular-Weight Heparin
Enoxaparin acts through antithrombin, with greater anti-Xa than anti-IIa activity.[5] The label's ratio of approximately 14:1 describes activity–time AUC after 1.5 mg/kg.[5]
| Adult setting | Dose / label distinction |
|---|---|
| Abdominal-surgery prophylaxis | 40 mg SC daily; the US label starts two hours preoperatively for a usual 7–10 days. Urologic guideline timing and extended duration may differ. [5] |
| CrCl <30 mL/min | 30 mg SC daily for abdominal-surgery prophylaxis. [5] |
| 30 mg twice daily | In the US label, 30 mg twice daily is the hip/knee replacement regimen, not the regimen for abdominal or pelvic surgery. A trauma guideline uses this dose in selected patients, but trauma is not a labeled indication.[5][31] |
| Low weight / obesity | Increased exposure or uncertain prophylactic efficacy warrants individualized assessment. The label does not prescribe universal 20-mg underweight or 40-mg-twice-daily obesity regimens. |
Pharmacokinetics (label): in healthy subjects, mean absolute bioavailability based on anti-Xa activity is approximately 100% after a 1.5 mg/kg subcutaneous dose; anti-Xa activity peaks 3–5 hours after the dose; half-life is 4.5 hours after a single dose and about 7 hours with repeated dosing. Clearance is renal: after repeated 40 mg subcutaneous once-daily doses, steady-state anti-Xa AUC is on average 65% higher when CrCl is below 30 mL/min. After a single 40 mg dose, anti-Xa exposure is 52% higher in women under 45 kg and 27% higher in men under 57 kg.[5]
Boxed warning: epidural or spinal hematoma in anticoagulated patients having neuraxial anesthesia or spinal puncture may cause long-term or permanent paralysis; the boxed text states that the optimal timing between enoxaparin and neuraxial procedures is not known. Section 5.1 of the label advises delaying catheter placement or removal at least 12 hours after lower doses (30 mg once or twice daily, 40 mg once daily) and at least 24 hours after higher doses (0.75 or 1 mg/kg twice daily, 1.5 mg/kg daily), and notes that anti-Xa activity is still detectable at those times. It suggests waiting at least 4 hours after catheter removal for the next dose. With CrCl below 30 mL/min it suggests doubling the removal interval (at least 24 hours after 30 mg daily, 48 hours after 1 mg/kg daily).[5]
Strengths and limits: once-daily dosing and predictable pharmacokinetics; subcutaneous injection is a compliance barrier, and renal accumulation requires dose review.
Monitor bleeding, CBC/platelets and renal function. Anti-Xa testing is selective, not routine; PT/aPTT do not reliably measure enoxaparin effect. Contraindications include active major bleeding, relevant hypersensitivity, and HIT within 100 days or circulating antibodies. Any HIT history warrants specialist review. Protamine reverses anti-Xa activity incompletely, at most approximately 60%.[5][6]
Unfractionated Heparin
UFH enhances antithrombin inhibition of thrombin and factor Xa. The label describes the most widely used low-dose regimen as 5,000 units SC two hours before surgery and every 8–12 hours thereafter for 7 days or until the patient is fully ambulatory, whichever is longer, by deep subcutaneous injection.[13] Choose the actual surgical start time with the operative/anesthesia team. Severe renal impairment can favor UFH because of its shorter, more readily reversible effect; it still requires bleeding and platelet surveillance. Weight-based escalations or reductions need an institutional protocol, not an automatic BMI rule.[13][12]
In severe renal impairment (CrCl below 30 mL/min), UFH may be preferred to LMWH because its effect is shorter and more readily reversed with protamine.[5][13] The trade-offs are dosing two or three times daily, less predictable response, and a higher HIT risk than LMWH, so platelet counts need surveillance.[13][25] UFH can cause hyperkalemia in chronic renal failure; check potassium before treatment in at-risk patients and periodically if treatment exceeds five days.[13]
UFH can cause HIT, is contraindicated in severe thrombocytopenia[13], and is not interchangeable with LMWH unit for unit.[5] Neuraxial compatibility depends on dose and timing.[13][6]
Oral Factor Xa Inhibitors
Apixaban
Apixaban is a direct factor Xa inhibitor. 2.5 mg orally twice daily is the studied prophylactic dose in the gynecologic cancer trial below.[14] Use after urologic cancer surgery is off-label in the US; FDA postoperative approval concerns hip/knee replacement.[8] ASCO supports it as a selected extended-prophylaxis option after initial heparin.[8][14][2]
Renal excretion accounts for approximately 27% of clearance. US labeled adult VTE indications have no renal dose adjustment, but efficacy/safety trials excluded dialysis and CrCl <15 mL/min. Reassess acute kidney injury, hepatic disease, bleeding and oral absorption. Avoid combined strong CYP3A4/P-gp inhibitors when already using 2.5 mg twice daily, and avoid strong combined inducers. Active pathological bleeding and severe hypersensitivity are formal contraindications. Neuraxial hematoma is a boxed-warning risk.[8]
| Setting | Apixaban dose |
|---|---|
| Postoperative prophylaxis after cystectomy or gynecologic cancer surgery (extended course) | 2.5 mg twice daily for 28 days in the gynecologic trial; off-label in urology.[14] |
| Hip or knee replacement (US label) | 2.5 mg twice daily starting 12–24 hours after surgery: 12 days for knee, 35 days for hip.[8] |
What the Main Studies Establish
| Study | Result | Limit |
|---|---|---|
| Guntupalli 2020, 400 women randomized after surgery for suspected/confirmed gynecologic cancer | Apixaban 2.5 mg twice daily versus enoxaparin 40 mg daily for 28 days. Major bleeding was 1/204 versus 1/196; VTE 2/204 versus 3/196. Oral administration was easier and less painful.[14] | Primarily a safety trial with few events and wide confidence intervals; no proof of equivalent efficacy for every urologic procedure. |
| Westerman 2022, prospective single-center quality-improvement study | Sequential enoxaparin (161 patients) and apixaban (154) periods: compliance barriers 33.5% versus 14.3%; 30-day postdischarge symptomatic VTE/major-bleeding composite 3.1% versus 0%.[9] | Met the prespecified noninferiority threshold and favored apixaban statistically, but not randomized. |
| SUO survey conducted in 2023, published online 2025 | Of 62 respondents, a 6% response rate, 98% reported extended prophylaxis after cystectomy and 70% prescribed apixaban.[7] | — |
Rivaroxaban
PROLAPS II randomized 582 patients after laparoscopic colorectal cancer surgery. Following LMWH from surgery to randomization at day 7±2, rivaroxaban 10 mg daily or placebo was given for three weeks. The day-28 composite of symptomatic VTE, screening-detected DVT or VTE-related death occurred in 3/287 versus 11/282 patients (1.0% versus 3.9%); major bleeding occurred in two rivaroxaban patients and none receiving placebo. Recruitment ended early because the study drug expired.[15]
Compared with apixaban, rivaroxaban is once daily, was started after a week of LMWH in that trial, and has less urologic evidence. For adults, its only US-labeled indication for DVT prophylaxis following surgery is hip or knee replacement (10 mg daily for 35 or 12 days, started 6–10 hours after surgery once hemostasis is established), and the label advises avoiding it when CrCl is below 15 mL/min.[28]
Verify the current agent-specific label, kidney/liver function and interactions when selecting it; do not substitute apixaban's renal rules.[2][15]
Bowel Resection and Oral Intake
Ileus, vomiting, inability to take oral medication or extensive intestinal resection can make oral prophylaxis unreliable. Consider a parenteral agent until absorption is dependable.[12][9]
Neuraxial Safety — Confirm Both Timing and Dose
ASRA fifth edition (2025): the following are selected adult intervals for standard low-dose regimens. Renal impairment, traumatic placement, other antithrombotics or higher doses require the full anesthesia plan. Surgical hemostasis requires assessment beyond minimum catheter intervals.[6]
| Regimen | Selected neuraxial requirements |
|---|---|
| Enoxaparin once-daily low dose | Placement ≥12 hours after last dose. First postoperative dose ≥12 hours after placement; second ≥24 hours later. Catheter may remain with appropriate precautions; remove ≥12 hours after last dose, then wait ≥4 hours before dosing. |
| Enoxaparin twice-daily low dose | First dose the following day and ≥12 hours after placement. Remove catheter before starting this regimen; wait ≥4 hours after removal. |
| UFH 5,000 units SC twice/three times daily | Placement and removal generally ≥4–6 hours after a dose. Catheter may remain; subsequent low-dose UFH may follow removal immediately. |
| Low-dose apixaban | Hold ≥36 hours before placement; placement/removal ≥6 hours before first postoperative dose. If inadvertently given with a catheter in place, withhold ≥36 hours or follow ASRA drug-level guidance before removal. |
| Low-dose rivaroxaban | Hold ≥24 hours before placement (≥30 hours if CrCl <30 mL/min); placement/removal ≥6 hours before first postoperative dose. A residual level <30 ng/mL (anti-Xa ≤0.1 IU/mL) is acceptable if placement is planned sooner. All ASRA grade IIC.[6] |
The product labels give their own catheter rules. Apixaban: do not remove an indwelling epidural or intrathecal catheter earlier than 24 hours after the last dose, give the next dose no earlier than 5 hours after removal, and delay dosing 48 hours after a traumatic puncture. Rivaroxaban: do not remove a catheter before two half-lives have elapsed (18 hours at ages 20 to 45, 26 hours at ages 60 to 76), give the next dose no earlier than 6 hours after removal, and delay dosing 24 hours after a traumatic puncture. Both carry a boxed warning for spinal or epidural hematoma.[8][28]
High-dose apixaban uses different intervals: ≥72 hours before placement and ≥24 hours from placement/removal to the first postoperative dose. Reduced renal clearance can prolong LMWH activity (half-life up to 16 hours in severe renal insufficiency, per ASRA); the usual 12-hour rule is insufficient as a blanket instruction in severe renal impairment, and ASRA describes the ESAIC/ESRA approach of doubling the interval or halving the dose when CrCl is below 30 mL/min, with an anti-Xa level of ≤0.1 IU/mL as the suggested acceptable residual.[6] An urgent new neurologic deficit after neuraxial anesthesia requires immediate assessment for hematoma.[6][5]
Intermittent Pneumatic Compression
IPC reduces venous stasis without adding an anticoagulant drug. It is a useful adjunct in selected high-risk surgical patients and an alternative while pharmacologic prophylaxis is unsafe.[12][1] Proper fit, actual wear and skin/limb assessment matter; assess arterial disease, wounds and suspected/known DVT against the device's instructions.[12][1]
The 2022 Cochrane review included 34 studies and 14,931 participants, mostly surgery or trauma. Adding IPC to pharmacologic prophylaxis reduced DVT (OR 0.38, 95% CI 0.21–0.70; high certainty) and PE (OR 0.46, 0.30–0.71; low certainty). Bleeding estimates were very uncertain.[10] Adding an anticoagulant to IPC alone also reduced VTE but increased bleeding.[10]
In immobile stroke patients (CLOTS 3, 2,876 patients), IPC reduced DVT.[27]
In contrast, PREVENT randomized 2,003 ICU patients already receiving pharmacologic prophylaxis and found no significant reduction in new proximal DVT with adjunctive IPC among those evaluable for the primary outcome: 37/957 (3.9%) versus 41/985 (4.2%), RR 0.93 (95% CI 0.60–1.44).[11]
Ambulation alone is not a substitute for formal prophylaxis in a high-risk patient; ACCP 2012 limits ambulation-only management to very-low-risk patients.[25]
Bleeding and Contraindications
Active significant bleeding may require withholding pharmacologic prophylaxis and using appropriate mechanical measures until reassessment. Platelet count, trend, cause of thrombocytopenia, recent bleeding, kidney/liver function and neuraxial procedures all affect that decision. In advanced liver disease, INR >1.5 appears as a bleeding-risk factor in a medical-inpatient model[33]; HIT and hypersensitivity contraindications are agent-specific. Reassess daily.[1][5][8][13]
A prophylactic IVC filter should not be used as a substitute for pharmacologic prophylaxis in a patient who cannot receive it. ASCO guidance does not recommend prophylactic filter placement for primary VTE prevention in major cancer surgery, because no randomized trial establishes benefit and the device carries long-term harms. Use mechanical prophylaxis and reassess for pharmacologic prophylaxis as bleeding risk falls instead; this is distinct from the ASCO option of a filter for acute VTE diagnosed within four weeks when anticoagulation is absolutely contraindicated and the thrombus burden is considered life-threatening.[2]
Procedure Summary
| Procedure | Practical approach |
|---|---|
| Cystectomy with diversion | Pharmacologic prophylaxis plus IPC; extended course of about 4 weeks with LMWH, or apixaban after an initial LMWH or UFH period in selected cancer patients . Total duration and stop date named at discharge.[12][1][2] |
| Open radical prostatectomy with extended lymphadenectomy | Pharmacologic prophylaxis per ESAIC 2024; extended course individualized.[12] |
| Robotic prostatectomy, nephrectomy, RPLND | Individualize by procedure, lymphadenectomy and patient risk. For robotic prostatectomy with extended lymphadenectomy, ESAIC 2024 recommends strongly against pharmacologic prophylaxis at low patient risk (none of age ≥75, BMI ≥35 or prior VTE) and strongly for it at high risk (both age/BMI factors or prior VTE). About 30% of surveyed SUO respondents used extended prophylaxis after RALP or RPLND.[12][7][21] |
| TURP | Not routine; ASH 2019 suggests against pharmacologic prophylaxis.[3] |
Renal Impairment After Diversion
Patients having cystectomy often have reduced renal function from obstruction, chemotherapy or a solitary kidney. Choose the agent for the current CrCl.
| Agent | CrCl below 30 mL/min |
|---|---|
| Enoxaparin | 30 mg once daily for abdominal-surgery prophylaxis.[5] |
| UFH | No renal adjustment; usual choice.[13] |
| Apixaban | Trials excluded CrCl below 15 mL/min; individualize.[8] |
| Rivaroxaban | At CrCl 15–<30 mL/min, exposure rises and clinical data are limited; observe closely for bleeding. Avoid below 15 mL/min.[28] |
Practical Pearls
- Radical cystectomy carries the highest urologic VTE risk, and more than half of events occur after discharge.[19][22]
- LMWH remains the established extended agent.[2] Among surveyed SUO respondents, apixaban was the most-prescribed option; they reported injection-adherence barriers for enoxaparin and cost/insurance barriers for apixaban.[7] A review of four nonrandomized comparative urologic studies (856 patients, mostly cystectomy), including Westerman’s prospective study, found no statistically significant VTE or bleeding difference between DOACs and LMWH at study-specific follow-up of 30 to 90 days; evidence is insufficient to determine equivalent efficacy.[9][32] A gynecologic-oncology randomized trial also informs selected apixaban use.[14]
- When CrCl is below 30 mL/min, UFH is an option; the labeled enoxaparin dose for abdominal-surgery prophylaxis is 30 mg SC daily.[5][13]
- Add IPC for high-risk cancer surgery; use it alone while pharmacologic prophylaxis is contraindicated.[10][25]
- Consider absorption before prescribing a DOAC after long bowel resection or with ileus.
- Coordinate enoxaparin with neuraxial catheter timing by regimen: for once-daily low-dose use, place or remove a catheter at least 12 hours after the last dose and give the next dose at least 4 hours after removal; remove the catheter before starting twice-daily low-dose use. With CrCl <30 mL/min, the label suggests waiting at least 24 hours before catheter removal after 30 mg once daily.[5][6]
See Also
- Antithrombotic therapy — procedure-specific workflow, bridging and antiplatelets
- Anticoagulation reversal — reversal pharmacology
- ERAS — enhanced recovery
- Post-op bowel & ileus management — oral-intake considerations
References
1. Farge D, Frere C, Connors JM, et al. "2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19." Lancet Oncol. 2022;23(7):e334–e347. doi:10.1016/S1470-2045(22)00160-7
2. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41:3063–3071. doi:10.1200/JCO.23.00294.
3. Anderson DR, Morgano GP, Bennett C, et al. "American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients." Blood Adv. 2019;3(23):3898–3944. doi:10.1182/bloodadvances.2019000975
4. Pannucci CJ, Swistun L, MacDonald JK, Henke PK, Brooke BS. "Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis." Ann Surg. 2017;265(6):1094–1103. doi:10.1097/SLA.0000000000002126
5. Sanofi. Lovenox (enoxaparin sodium) prescribing information. Revised May 2025 (pharmacodynamics and pharmacokinetics, sections 12.2–12.3, and overdosage, section 10, checked September 27, 2026); the generic enoxaparin label effective February 2026 carries the same boxed warning and section 5.1 text. DailyMed.
6. Kopp SL, Vandermeulen E, McBane RD, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: ASRA evidence-based guidelines (fifth edition). Reg Anesth Pain Med. 2025 (published online January 29). doi:10.1136/rapm-2024-105766.
7. Slinger M, Michel KF, Xia L, et al. "Perioperative use of venous thromboembolism prophylaxis following major urologic oncology surgeries: a survey of the Society of Urologic Oncology." Urol Oncol. 2026;44(2):102–108. doi:10.1016/j.urolonc.2025.10.020
8. Bristol Myers Squibb / Pfizer. Eliquis (apixaban) prescribing information, revised April 2025 (E.R. Squibb & Sons label; clinical pharmacology section 12.3 checked September 27, 2026). DailyMed.
9. Westerman ME, Bree KK, Msaouel P, et al. "Apixaban vs enoxaparin for post-surgical extended-duration venous thromboembolic event prophylaxis: a prospective quality improvement study." J Urol. 2022;208(4):886–895. doi:10.1097/JU.0000000000002788
10. Kakkos S, Kirkilesis G, Caprini JA, et al. "Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism." Cochrane Database Syst Rev. 2022;1:CD005258. doi:10.1002/14651858.CD005258.pub4
11. Arabi YM, Al-Hameed F, Burns KEA, et al. "Adjunctive intermittent pneumatic compression for venous thromboprophylaxis." N Engl J Med. 2019;380(14):1305–1315. doi:10.1056/NEJMoa1816150
12. European guidelines on peri-operative venous thromboembolism prophylaxis: first update. Chapter 12: Urology. Eur J Anaesthesiol. 2024. Full text.
13. Heparin sodium injection prescribing information, label effective September 2025. DailyMed.
14. Guntupalli SR, et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open. 2020;3:e207410. doi:10.1001/jamanetworkopen.2020.7410.
15. Becattini C, et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood. 2022;140:900–908. doi:10.1182/blood.2022015796.
16. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. "Prevention of venous thromboembolism in gynecologic surgery: ACOG Practice Bulletin, Number 232." Obstet Gynecol. 2021;138(1):e1–e15. doi:10.1097/AOG.0000000000004445
17. Bauer HH, Schlussel MA, Rhodes SP, Hijaz AK, Sheyn D. "Impact of pharmacologic thromboprophylaxis on venous thromboembolism and bleeding complications following pelvic organ prolapse procedures." Int Urogynecol J. 2026;37(3):719–729. doi:10.1007/s00192-025-06375-9
18. Klaassen Z, Arora K, Goldberg H, et al. "Extended venous thromboembolism prophylaxis after radical cystectomy: a call for adherence to current guidelines." J Urol. 2018;199(4):906–914. doi:10.1016/j.juro.2017.08.130
19. VanDlac AA, Cowan NG, Chen Y, et al. "Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis." J Urol. 2014;191(4):943–947. doi:10.1016/j.juro.2013.10.096
20. Najdi J, Ayoub CH, Chawareb EA, et al. "Preoperative risk factors for venous thromboembolism in major urologic cancer surgeries." World J Urol. 2024;43(1):10. doi:10.1007/s00345-024-05372-9
21. Naik R, Mandal I, Hampson A, et al. "The role of extended venous thromboembolism prophylaxis for major urological cancer operations." BJU Int. 2019;124(6):935–944. doi:10.1111/bju.14906
22. Sun AJ, Djaladat H, Schuckman A, et al. "Venous thromboembolism following radical cystectomy: significant predictors, comparison of different anticoagulants and timing of events." J Urol. 2015;193(2):565–569. doi:10.1016/j.juro.2014.08.085
23. Knoll W, Fergusson N, Ivankovic V, et al. "Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis of the literature." Thromb Res. 2021;204:114–122. doi:10.1016/j.thromres.2021.06.010
24. Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. "Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis." Ann Surg Oncol. 2016;23(5):1422–1430. doi:10.1245/s10434-016-5127-1
25. Gould MK, Garcia DA, Wren SM, et al. "Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines." Chest. 2012;141(2 Suppl):e227S–e277S. doi:10.1378/chest.11-2297
26. Lobastov K, Urbanek T, Stepanov E, et al. "The thresholds of Caprini score associated with increased risk of venous thromboembolism across different specialties: a systematic review." Ann Surg. 2023;277(6):929–937. doi:10.1097/SLA.0000000000005843
27. Dennis M, Sandercock P, Reid J, et al. "Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial." Lancet. 2013;382(9891):516–524. doi:10.1016/S0140-6736(13)61050-8
28. Janssen Pharmaceuticals. Xarelto (rivaroxaban) prescribing information, label effective September 2026. DailyMed.
29. American Urological Association / American Society of Clinical Oncology / Society of Urologic Oncology. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer. Amended 2024. Statement 16 and discussion. Guideline PDF.
30. Lavikainen LI, Guyatt GH, Kalliala IEJ, et al. "Risk of thrombosis and bleeding in gynecologic noncancer surgery: systematic review and meta-analysis." Am J Obstet Gynecol. 2024;230(4):390–402. doi:10.1016/j.ajog.2023.11.1255
31. Ley EJ, Brown CVR, Moore EE, et al. "Updated guidelines to reduce venous thromboembolism in trauma patients: a Western Trauma Association critical decisions algorithm." J Trauma Acute Care Surg. 2020;89(5):971–981. doi:10.1097/TA.0000000000002830
32. Ramadhan M, AlMehandi A, Al-Naseem A, Hayat J, Almarzouq A. "Prophylactic direct oral anticoagulants vs. low molecular weight heparin after urological surgery: a systematic review and meta-analysis." Arab J Urol. 2025;23(1):84–94. doi:10.1080/20905998.2024.2395202
33. Agency for Healthcare Research and Quality. “Chapter 4. Choose the Model To Assess VTE and Bleeding Risk.” Preventing Hospital-Associated Venous Thromboembolism: A Guide for Effective Quality Improvement. Reviewed October 2022. Source.